Dementia, defined as deterioration in several cognitive domains, is a major public health problem that threatens to become the scourge of the 21th century. It is caused by dysfunction/loss of synapses and neurons inducing default neuronal networks. Consensus criteria for the diagnosis of different dementia disorders have recently been updated. Clinical diagnostic accuracy using revised research criteria and new chemical, imaging and genetic biomarkers ranges from 65 to 96% (for Alzheimer disease), with a sensitivity versus other dementias of 71 to 87% and specificity of 44 to 71%. Morphological assessment, using immunohistochemistry, molecular biological and genetic methods and based on homogenous definitions, harmonized inter-laboratory methods and assessment standards, can achieve a diagnosis/classificaion in almost 99%, without, however, clarifying the etiology of most of these disorders. The new National Institute on Aging-Alzheimer Association (ABC) guidelines for pathological diagnosis of Alzheimer disease combine β-amyloid plaque phases, Braak neurofibrillary and neuritic plaque scores, also considering other pathologies. Major difficulties arise from recent separation of distinct clinico-pathological subtypes (tangle-and plaque intensive, tangle predominant, limbic-predominant and -sparing) from classical Alzheimer disease. Revised research criteria are available for dementia with Lewy bodies, Parkinson disease-dementia, frontotemporal lobe degeneration, vascular cognitive impairment/dementia, prion diseases, and other neurodegenerative dementias. However, due to considerable overlap between various neurodegenerative proteinopathies and cases with mixed pathologies, human postmortem studies entail numerous biases that affect both their general applicability and the validity of correlations. Although most neurodegenerative dementias are incurable at present, concerted prospective clinico-pathological studies using validated protocols and data fusion are required to overcome the limitations of the current diagnostic framework as a basis for efficient new therapy options.
Introduction
Dementia (ICD-10 F00-F07), encompasses deteriorations in several cognitive domains (Dubois et al., 2010) . Although redefined as the manifestation of deteriorating brain functions over time as a part of aging due to cell deaths in the brain caused by neurodegeneration or any other disease (Peng, 2003) , recent research showed that it is not only caused by neuronal cell death/loss, but rather by dysfunction and loss of synapses already occurring in early AD (Reddy et al., 2005) and in α-synucleinopathies, eg, Parkinson disease (PD) and dementia with Lewy bodies (DLB) (Schulz-Schaeffer, 2010) , and by cholinergic neuronal and axonal abnormalities being present in aging and AD (Geula et al., 2008; Mufson et al., 2012) . These changes induce disconnection of important nervous circuitries causing default networks (McCaffrey et al., 2010; Palop and Mucke, 2010; Pievani et al., 2011; Schroeter et al., 2012 ) that have been demonstrated in vivo in early AD (Wang et al., 2007) , suggesting that disease progress is transmitted by neuronal pathways (Raj et al., 2012 ).
Both the prevalence and incidence of dementia increase exponentially with age and double every five years (f. rev. see Alzheimer's Association, 2012) . With the disproportional growth of the elderly population, dementia has become a major public health and socio-economic problem that threatens to become the scourge of our century.
Consensus criteria for the clinical diagnosis of the major dementing disorders have recently been updated, e.g., the revised NICDS-ADRDA and EFNS criteria for AD (Dubois et al., 2010; Sorbi et al., 2012) , the National Institute on Aging-Alzheimer's Association (NIA-AA) criteria for AD Reiman et al., 2011; Sperling et al., 2011; Sarazin et al., 2012) , for Parkinson diseasedementia (PDD) Emre et al., 2007) , DLB (McKeith et al., 2005) , frontotemporal lobe degeneration (FTLD) (Josephs et al., 2011; Seltman and Matthews, 2012) , vascular dementia (VaD) or vascular cognitive disorder (SCADDTD) (Chui et al., 2000) ; NINDS-AIREN DSM-IV (Gorelick et al., 2011) , and other degenerative dementias (Karantzoulis and Galvin, 2011; .
Assessment of clinical data with fusion of different biomarkers has already improved the clinical diagnostic accuracy of AD up to 96%, while their sensitivity and specificity versus other dementias is 23-88% (Jellinger, 2011) . A combination of the best CSF and MRI data will lead to a more precise diagnostic prediction (Vanderstichele et al., 2012; Zabel et al., 2012) , and will be further increased by using multimodal techniques and novel CNS biomarkers (Bloudek et al., 2011; Abdi et al., 2012; Blennow et al., 2012; Doecke et al., 2012; Engelborghs and Le Bastard, 2012; Fagan and Perrin, 2012; Johnson et al., 2012; JC Price, 2012; Teipel et al., 2012; Toledo et al., 2012) . The validity of plasma biomarkers for the (preclinical) diagnosis of AD is under discussion (Koyama et al., 2012) . Identification of fibrillar Aβ in vivo by [(11)C]-PIB PET is a valuable tool for the prospective evaluation of the development and progression of cognitive impairment (Kadir et al., 2011; Sojkova et al., 2011b; Villemagne et al., 2011; Beckett et al., 2012; Clark et al., 2012; Villain et al., 2012) . Evaluation of biopsied or postmortem brain samples indicated that PiB binding in vivo correlated with heavy cerebral amyloid deposition (Svedberg et al., 2009; Sojkova et al., 2011a; Clark et al., 2012) . Recent demonstration that SDS-soluble Aβ measured by immunoessay was better than post mortem PiB binding has important implications for imaging-based biomarkers .
Hippocampal atrophy in the elderly demonstrated by modern imaging methods is confirmed by postmortem diagnosis of AD (Dawe et al., 2011; Teipel et al., 2012) . However, histopathology is still considered to add to premortem diagnostic accuracy (Durand-Martel et al., 2010; Jellinger, 2010a; Beach et al., 2012) . Clinico-pathological correlations in the most common neurodegenerative dementias were summarized recently (Taipa et al., 2012) .
A review of 2861 neurodegenerative disease cases of the National Alzheimer's Coordinating Center Registry (NACCR) showed high diagnostic accuracy for AD (85% sensitivity, 51.1% specificity) and low sensitivity for DLB (32% for pure AD and 12% for AD+DLB) with a specificity over 58% (Nelson et al., 2010b) . Evaluation of the accuracy of currently used clinical diagnostic methods for AD of 919 autopsy cases from the database of the NACC (2005) (2006) (2007) (2008) (2009) (2010) ) revealed a sensitivity from 70.9 to 87.3% and a specificity of 44.3 to 70.8%. When the clinical diagnosis was not confirmed by minimum levels of AD pathology, the most frequent primary diagnoses were tangle-only dementia, argyrophilic grain disease, FTLD, CVD, LBD, and hippocampal sclerosis. 39% of these cases met or exceeded minimum threshold levels of AD histopathology. The misdiagnosis rate should be considered when estimating numbers for AD studies . In a recent clinicopathological restudy of 200 demented brain donors (mean age 78.7±6.9 years, 26% AD, 15.5% mixed dementia, 28% combined diagnoses), the overall agreement between clinical and postmortem diagnoses was 44% (85% for prion disease, 49% for AD), and there was frequent cooccurrence of multiple pathological disorders (Echavarri et al., 2012) .
The aim of this review is to discuss the diagnostic validity of currently used neuropathological criteria of neurodegenerative dementias and their limitations as well as to give recommendations for future clinico-pathological research. The diagnosis of young-onset dementia presents challenges that differ from those of older patients. Much of our understanding of the pathogenesis of the degenerative dementias has been driven by the identification of genetic mutations causing earlyonset familial disease .
Challenges of the updated pathological diagnostic criteria
At present, several diagnostic guidelines for the neuropathological diagnosis of most dementing disorders are used, relying on qualitative, semiquantitative, and topographic assessment of morphological and bio/histochemical sign posts, in particular specific protein inclusions in neurons, glia and other cells (Jellinger, 2010b; . The classification of neurodegenerative disorders, previously based on the anatomical systems involved, has been progressively replaced by molecular diagnosis (Jellinger and Kovacs, 2011) . A simplified molecular-pathologic classification of degenerative dementias is given in Fig. 1 . This will form the basis for their neuropathological diagnosis in the future. The frequency of the most frequent forms of dementia according to several autopsy series is given in Figs. 2a and 2b.
Neuropathological criteria for Alzheimer disease (AD), in addition to cut-off quantitative values of senile plaques and tangles (Duyckaerts and Dickson, 2011; Serrano-Pozo et al., 2011) , their semiquantitative assessment and age-adjustment in the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) protocol (Mirra et al., 1991) , include the topographical staging of neuritic AD pathology (Braak and Braak, 1991) , re-evaluated recently (Braak et al., 2006b; Alafuzoff et al., 2008a) , as well as the progress and distribution of Aβ deposition being different (Thal et al., 2002) . A growing body of evidence supports the idea that plaques and NFTs actually define (but not fully represent) the disease process, which also involves oxidative stress, neuroinflammation, synaptic, neuronal, and axonal dysfunction and loss (Serrano-Pozo et al., 2011) . All these changes begin before significant cognitive decline occurs. The generally used combination of the CERAD and Braak scores in the National Institute of Aging-Reagan Institute (NIA-RI) criteria relates dementia to AD-typical lesions with high, intermediate and low likelihood (Hyman and Trojanowski, 1997) . These categories of AD diagnosis apply only to individuals with dementia, and the evaluation of the NIA-RI critera demonstrated their easy and rapid use in AD and nondemented subjects, but much less reliability for other dementing disorders. High Braak stages and CERAD criteria identified 54% and 97% of AD cases, respectively, and eliminated between 62 and 100% of nondemented ones with low Braak stages, whereas among non-AD neurodegenerative dementias only between 8 and 42% were identified (Jellinger, 2009a) .
Fig 1. Molecular-pathologic classification of degenerative dementias
A consensus panel recently updated and revised the 1997 guidelines for the neuropathological evaluation of AD and other diseases of brain in the elderly Montine et al., 2012) . Major revisions include (1.) recognition that AD neuropathology may occur in the apparent absence of cognitive impairment, (2.) an "ABC" score for AD neuropathology changes that incorporates histological assessments of Aβ deposits (A), based on the phase assessment of amyloid (Thal et al., 2002) , staging of neurofibrillary tangles /NFT) (B), based on the Braak staging system, and scoring of neuritic plaques (C), based on CERAD criteria (Mirra et al., 1991; Kovacs and Gelpi, 2012) (Table 1) , and (3.) more detailed approaches for assessing co-morbid conditions, such as LB disease, vascular brain injury, hippocampal sclerosis, and TAR DNA binding protein immunoreactive lesions . Correlations between neuropathological AD changes with cognitive status were reviewed recently . α-Synucleinopathies, in particular Lewy body disorders (PD and DLB), show a multi-organ distribution of phosporylated αSyn, with earliest involvement of the gastrointestinal tract and olfactory bulb (Braak et al., 2003; Braak et al., 2006a; Braak et al., 2006b; Beach et al., 2010; Jellinger, 2012c) . In addition to assessment criteria (Alafuzoff et al., 2008b) , staging/classification systems based on the semiquantitative assessment of the distribution and progression pattern of αSyn pathology are used (McKeith et al., 2005; Alafuzoff et al., 2009 ) that are suggested to indicate a predictable sequence of lesions (Braak et al., 2003; Braak et al., 2006a; Braak et al., 2006b ). Recent clinico-pathological studies, although partly confirming this system (Kingsbury et al., 2010) , have shown that between 6.3 and 47% of autopsy-proven PD cases did not follow the proposed caudorostral spread of Lewy pathology (Braak et al., 2003; Burke et al., 2008; Jellinger, 2008b; Parkkinen et al., 2008; Jellinger, 2009b Jellinger, , 2012c . In 7-8.3% of PD cases, the dorsal motor nucleus of vagus was not involved despite definite αSyn inclusions in the higher brainstem or even in cortical regions (Parkkinen et al., 2008; Zaccai et al., 2008; Jellinger, 2009b) . On the other hand, 30-55% of elderly subjects with widespread/cortical αSyn pathology revealed no definite neuropsychiatric symptoms or were not classifiable (Fujishiro et al., 2008; Leverenz et al., 2008; Zaccai et al., 2008) . Therefore, the criteria for categorization of Lewy-related pathology have been modified (Table 2) . It is important to note that this classification is focused on the clinical context of cognitive impairment or dementia. LBD also occurs early in olfactory bulb, and even can occur outside of the brain.
PD-dementia (PDD) and DLB, sharing many clinical and morphological features, are believed to form a continuum within the spectrum of LB diseases (McKeith et al., 2005; Ballard et al., 2006; Gross et al., 2008) . Clinically, an arbitrary cut-off is used: if dementia develops first or within one year of PD diagnosis, then DLB is diagnosed, while PD followed first or within one year of PD diagnosis suggests PDD. Their pathological hallmarks are αSyn/LB pathology or a variable mixture of LB and AD pathologies, which may act synergistically (Compta et al., 2011) . According to revised guidelines, the severity and extent of αSyn are scored semiquantitatively in specific brain regions (McKeith et al., 2005; Alafuzoff et al., 2009) . DLB differs from PDD by more severe diffuse amyloid load in the striatum (Jellinger and Attems, 2006; Halliday et al., 2011) , and more frequent LB affection of the hippocampal CA 2-3 subareas (Jellinger, 2012c) . DLB cases had more severe Aβ load than PDD; but no differences in neuritic and αSyn scores, while others reported higher Aβ load in cortical and subcortical areas (Compta et al., 2011; Kalaitzakis et al., 2011) , the Aβ load being similar to that in AD (Dugger et al., 2012; Gomperts et al., 2012) . Between 10 and 50% of PDD brains had enough AD lesions to attain the pathological diagnosis of definite AD (Sabbagh et al., 2009 ), but cognitive impairment may also be related to higher Braak LB stages in the absence of significant AD pathology (Braak et al., 2005) . A recent clinico-pathological study showed that cortical LB/LN pathology is the most significant correlate of dementia in PD, while AD pathology, being abundant in a subset of patients, may modify the clinical phenotype (Irwin et al., 2012) . On the other hand, up to 50% of PD cases exhibit additional LB pathology, which is associated with a more aggressive disease course and accelerated cognitive dysfunction (Clinton et al., 2010) .
Frontotemporal lobe degeneration (FTLD)
, the third or forth most frequent cause of dementias, includes three major clinical subgroups: behavior variant (bvFTD), semantic dementia (SD), and progressive non-fluent aphasia (PNFA) , their molecular correlates according to the predominant protein aggregates are: microtubulus-associated tau protein (FTLD-tau), TAR-DNA binding protein-43 (FTLD-TP-43), and fusion sarcoma protein (FTLD-FUS), but there are cases with overlapping pathology Goedert et al., 2012; Halliday et al., 2012; Seltman and Matthews, 2012) . Criteria for the neuropathological diagnosis based on biochemical markers are summarized in Fig. 3 . A small group of FTLD patients clinically mimicking DLB has been identified, which morphologically was consistent with TDP-43 proteinopathy (Claassen et al., 2008) . Up to 40% of FTD patients have a familial background, and 30-50% of familial cases show autosomal-dominant traits; furthermore, various gene mutations have been described (Goedert et al., 2012) . FTLD in elderly patients presents features of several phenotypes and morphological subgroups similar to that seen in the presenile group, though patients with MAPT (tau-gene), but not progranulin mutations or FUS pathology are rare or even absent (Baborie et al., 2010) . However, these authors found significantly more frequent hippocampal sclerosis but milder frontal atrophy in the elder group (Baborie et al., 2012) . This was confirmed in two personal cases of FTLD tau at age 85 and 88 years, respectively, but further clinico-pathological studies in this rare subtype of dementia are warranted. TDP-43 positive inclusions also are observed in cases with AD and LB pathologies (Arai et al., 2009) , and FUS-immunoreactive intranuclear inclusions occur in various neurodegenerative diseases (Woulfe et al., 2010) , but it is not clear whether these changes are a primary, secondary or coincidental event (AC Wilson et al., 2011) .
For vascular dementias (or vascular cognitive impairment/diseases related to cerebrovascular disease /CVD/), despite various proposals for a categorization of major cerebrovascular lesions (CVLs) (Chui et al., 1992; Román et al., 1993; Kalaria et al., 2004; Jellinger, 2007b) , a harmonization of the criteria and techniques for the assessment of cerebral lesions of presumable/possible vascular origin in cognitively impaired is necessary (Pantoni et al., 2006; Alafuzoff et al., 2012) . Due to the high variability of morphological findings and multifactorial pathogenesis of vascular cognitive impairment, no generally accepted morphologic scheme for quantitating cerebrovascular lesions and no validated neuropathological criteria for vascular dementia have been established to date (see Jellinger, 2007b Jellinger, , 2008a Román, 2008) . The revised NIA-AA guidelines recommend reporting all macroscopic and microscopic CVLs, multiple such lesions being associated with increased likelihood of cognitive impairment . Another recent staging strategy proposing semiquantitative assessment of CVLs in 4 brain areas with a score ranging from I to IV/VI (Table 3) (Deramecourt et al., 2012) needs further evaluation. Mixed type dementia, being frequent in elderly subjects, is diagnosed when a combination of several pathologies, e.g. AD with cerebrovascular lesions and /or Lewy pathology, is present (Jellinger, 2007a; Ferrer, 2010) . CVD and vascular brain injury (VBI) commonly are encountered in the brains of seniors with and without AD pathology (Jellinger, 2007a, b; Ferrer, 2010; Grinberg and Thal, 2010) ; but uniform and reproducible criteria are currently not available.
Prion diseases (transmissible spongiform encephalopathies/TSE) are rare and fatal neurodegenerative disorders, characterized by tissue deposition of a misfolded isoform of the cellular prion protein (PrP), commonly referred to as PrP Sc (Prusiner, 1998) . They are classified by both clinicopathological syndromes and etiology with subclassification according to molecular criteria (Wadsworth and Collinge, 2011; Safar, 2012) . Human prion diseases are grouped into three etiologic categories (Table 4): (1) sporadic Creutzfeldt-Jakob disease (sCJD) -age at onset 50-78 (mean 60) years, mean duration 5 months -, sporadic familial insomnia (sFI), and the recently described variably protease-sensitive prionopathy (VPSPr) (Zhao et al., 2010; Gambetti et al., 2011b) ; (2) inherited (genetic or familial) forms such as Gerstmann-Sträussler-Scheinker disease (GSS), fatal familial insomnia (FFI), octapeptide repeat insert (OPRI) (Cochran et al., 1996; Jansen et al., 2011) , rare familial prion disease with AD-like tau pathology (Jayadev et al., 2011) , genetic CJD associated with the E200K mutation , and (3) acquired forms, such as iatrogenic CJD (iCJD), Kuru, and variant CJD (vCJD) (transmission of bovine spongiform encephalopathy/BSE/ to humans) -age at onset 12-74 (mean 27) years, mean duration 14 months (Heath et al., 2011) . More than 80% of human prion diseases manifest as sCJD with an incidence of 1-2 cases per million population per year across the world. Around 15% are associated with autosomal dominant pathogenic mutations of the PRNP gene located on the short arm of chromosome 20. To date, 37 pathogenic mutations and 29 non-coding polymorphisms have been described (Capellari et al., 2011) . In contrast, acquired human prion diseases are rare (only 5% of human prion diseases): transmission of sCJD prions occurred through treatment with pituitary hormones pooled from human cadavers, transplantation of dura mater or cornea, the use of contaminated EEG electrodes, and by cannibalism among the Fore linguistic group in Papua New Guinea (Collinge et al., 2006) . Instead, vCJD occurred mainly in the UK and in other countries due to human exposure to BSE prions, and more recently in a few cases by transmission of vCJD contaminated blood products (Brandner, 2011) . In addition, there are mixed kuru plaques and other mixed morphological cases (MV 2K+2X, and VV2+1 subtypes), about 6 % of cases .
Based on this and other, slightly different definitions (Gambetti et al., 2011a; Gambetti et al., 2011b) and on the distribution and severity of histopathological lesions, a general nomenclature for the histopathological diagnosis of sCJD in the absence of molecular data was proposed (Table 5 ).
According to a recent inter-rater study among surveillance centers in Europa and USA, the use of this consensus classification of human prion disease histotypes allows reliable identification of molecular subtypes with full agreement for the two most common sCJD subtypes and vCJD, and very high concordance for all pure phenotypes and the most common subtypes with mixed phenotypic features . These data support the basis for the current classification of human prion disease and indicate that, besides molecular PrP Sc typing, histopathological analysis permits reliable disease classification with high inter-laboratory accuracy. In contrast to most dementing conditions that typically develop over years, rapidly progressive dementia (RPD) being quickly fatal is one of the most challenging problems. The differential diagnosis is often widely ranging, and, in addition to frequent prion diseases includes rapidly progressing neurodegenerative tauopathies and synucleinopathies, autoimmune condition infections, toxic-metabolic and neoplastic diseases (Geschwind et al., 2008; Josephs et al., 2009 ). According to the US National Prion Disease Pathology Surveillance Center (NPDPSC) in patients with RPD, treatable disorders are frequently mistaken for CJD. Among 1,106 brain autopsies, 32% were negative for prion disease; most frequent were AD (50%) and VaD (12%), while 23% were potentially treatable diseases, eg., immune-mediated, infectious disorders or tumors (Chitravas et al., 2011) . In these and other unclear conditions, both combined CSF markers (14-3-3 protein, extremely high total-tau or phospho-tau and Aβ(42) are sensitive indicators (Zanusso et al., 2011) . In a rapidly progressing form of AD that clinically may mimic CJD, the genetic profile (absence of ApoE ε4 homozygenity and biomarkers) differs from classical AD, suggesting that it might represent a distinct subtype of AD . Recent studies showed correlation between CSF biomarkers for AD with amyloid plaques and tau pathology in cortical brain biopsies (Seppälä et al., 2012) , although biopsy findings in demented subjects frequently are non-specific , with an overall sensitivity of 65% (Josephson et al., 2007) .
Problems may arise in the clinical diagnosis of early onset dementias, but recent studies showed that, despite absence of absolute concordance between clinical phenotype and underlying pathology, they can be distinguished with high accuracy. Among 228 cases with early-onset dementia, 46% were diagnosed with AD and the remaining cases DLB, CJD, VaD, or unclassified dementia. AD was identified with 97% sensitivity and 100% specificity, FTLD with 100% sensitivity and 97% specificity . Non-degenerative non-vascular cases of dementia being more common than expected in patients with a younger onset (30% of younger-onset and 5% of older-onset group aged 70-99 years) include cancer, chronic alcoholism, chronic mental illness, and others .
Specific problems in the diagnosis of Alzheimer disease
Histopathological examination of the brain establishes that AD-related lesions are present in sufficient densities to distinguish AD from age-related lesions and allows detection of other dementing disorders (Duyckaerts et al., 2009; Hyman et al., 2012; Montine et al., 2012) . The current algorithms for the neuropathological diagnosis of AD are based on (semiquantitative) assessment of plaques and tangles. Despite reasonable inter-rater agreement when using standardized criteria (Mirra et al., 1994; Bancher et al., 1997; Nagy et al., 1997b; Alafuzoff et al., 2008a) , no one set of histopathological criteria for AD has been uniformely accepted by neuropathologists. The previous algorithms that only considered the classical "plaque and tangle" phenotype of AD did not recognize other subtypes. Analysis of 1677 cases with antemortem diagnosis of dementia from the NACCR showed that 82.4% fell into diagnostic "boxes" that are within the consensus recommendations, while the others were "atypical" cases (Nelson et al., 2010c ). An atypical varient of AD, known as posterior cortical atrophy (PCA) morphologically shows greater NFT burden in the occipital and parietal lobes and lower in hippocampus (Levine et al., 1993 ), while we recently published a 4-repeat tauopathy clinically presenting as PCA .
The "plaque predominant" type with abundant amyloid plaques, no or very little neuritic pathology restricted to the hippocampus and abnormal phosphorylated tau in neocortical pyramidal cells but lacking overt tangle formation, accounts for 3.5-8% of demented subjects over age 85 (Terry et al., 1987; Tiraboschi et al., 2004) . Many of them are associated with cortical Lewy bodies representing a specific type of DLB or LB variant of AD (LBV/AD) (Hansen et al., 1990) . The "tangle predominant dementia" (TPD) with tau pathology often restricted to the limbic system, absence of neuritic plaques, no or very little (diffuse) amyloid plaques and rare amyloid angiopathy accounts for 5-7% of oldest olds with low ApoE ε4 frequency. Recent molecular and genetic analysis confirmed an identical tau isoform composition in TPD and AD (Jellinger and Attems, 2007) . It demonstrated absence of soluble Aβ but elevated soluble amyloid precursor protein alpha (APPα) in brain tissue, and association with the tau gene MAPT H1 haplotype, classifying it as a specific tauopathy independent of amyloid (Santa-Maria et al., 2012).
A recent clinico-pathological study of autopsy-proven AD cases separated distinct subtypes:
(a)hippocampal-sparing forms with lower NFT counts in hippocampus but more frequent senile plaques compared to typical AD (11%), (b) limbic-predominant forms (LP-AD) with lower cortical NFT counts and tau burden (14%), and (c) typical AD (75%). Hippocampal-sparing cases were younger at death; while the disease duration in all three types was similar . Additional vascular pathology ranged from 16 to 36%; while Lewy pathology (11-26%) was lowest in hippocampal-sparing form. While MAPT H1H1 genotype was high (~70 %) in TPD and LP-AD and similar to typical AD, tau and Aβ burden in frontal cortex were very low in TPD, differentiating it from AD subtypes, including the LP form. Significant pathological differences between TPD and LP-AD suggest that it may not merely be a variant of AD (Janocko et al., 2012) . Volumetric MRI analysis could reliably track the distribution of NFT pathology and predict pathological subtypes of AD at autopsy (Whitwell et al., 2012) .
Among 933 autopsy-confirmed AD cases, typical AD accounted for 82.5%, hippocampal-sparing and limbic-predominant form for 8.2 and 8.9%, respectively. Disease duration was lowest in limbicpredominant cases; age at death highest in typical AD. Additional cerebrovascular pathology was similar in all three types, Lewy pathology most frequent in hippocampal-sparing form (Jellinger, 2012b) (Table 6 ). These two studies and another one from the NACCR, separating "tangle intensive" and "plaque intensive" cases from "classic" AD (Nelson et al., 2010b) emphasize the need for prospective clinico-pathological studies for further elucidation of various phenotypes of AD. Standard metrics for tangles and neuritic plaques are usually semi-quantitative (Mirra et al., 1994; Hyman and Trojanowski, 1997; Hyman et al., 2012; Montine et al., 2012) and, according to the BrainNet Europe consortium, good agreement can be reached in the diagnosis only when the lesions are substantial, e.g., when having reached isocortical structures (Braak stage V-VI with absolute agreement 91%), while for mild lesions the agreement was poorer (Braak stage I-II, agreement 50%) (Alafuzoff et al., 2008a) , thereby limiting the ability to make accurate correlation of antemortem cognitive status and morphological findings (Jellinger, 2011; Nelson et al., 2012) .
Although the sensitivity and specificity of the NIA-RI criteria is suggested to be 90%, only 30 to 57% of the brains of patients with the clinical diagnosis of probable AD show "pure" AD pathology (Jellinger, 2011) . Thus, their predictive value may be reduced to 38-44% (Bowler et al., 1998) .
Testing the revised NIA-AA guidelines for the neuropathological assessment of AD in 390 autopsy cases (including 199 non-demented individuals) distinguished between pure AD and non-AD dementia as well as non-demented cases with a sensitivity of 71% and a specificity of 99%. The sensitivity increased after neuropathological exclusion of non-AD dementia cases, indicating that cognitive status and assessment according to NIA-AA guidelines appear ideal for distinguishing pure AD from non-AD dementia, preclinical AD (non-demented cases with a low NIA-AA degree of AD pathology), and normal controls (Thal et al, submitted) .
In a retrospective clinicopathological study of 1,700 demented elderly persons (66% female; MMSE score <20; mean age at death 84.3±6.0 years; 90% over age 70 years), AD-related lesions were present in 83.2%, but pure AD (ABC 3/3/3) without other pathologies in only 41.0%, AD with other pathologies including mixed dementia in 44.8%, vascular dementia in 10.7%, other disorders in 5.5%, and negative pathology in 0.9% (Jellinger, 2009a (Jellinger, , 2011 . Although cognitively normal elderly may show variable neocortical AD-related pathology, in general, the number of isocortical tangles correlates best with the severity of cognitive impairment (Nelson et al., 2007; Nelson et al., 2009; Markesbery, 2010; Nelson et al., 2012) . The pattern of gray matter loss associated with tangle pathology is an appropriate in vivo surrogate indicator of AD pathology (Whitwell et al., 2008) . The predictive value of widespread tau pathology (Braak stages V-VI) for dementia is high (Nelson et al., 2007; Nelson et al., 2012) , while others found that both diffuse and neuritic plaques, rather than tangles in neocortical regions distinguish nondemented and AD subjects with high sensitivity and specificity (McKeel et al., 2004) . A recent study found that the amyloid stage that has progressed to involve the striatum is highly predictive of dementia . However, there is considerable heterogeneity in morphology, extent and topographical distribution of Aβ deposits in brains with fully developed AD. The cortical Aβ burden usually does not correlate with disease duration and the stage of tau pathology (Cupidi et al., 2010) .
Dementia in the oldest-old
Neuropathology of AD in dementia in the old subjects differs considerably in both intensity and distribution from that in younger age groups (von Gunten et al., 2005) . Increased densities of neuritic plaques and NFTs are absent in non-demented patients over age 85-90 (Polvikoski et al., 2006; Prohovnik et al., 2006; Haroutunian et al., 2008; Nelson et al., 2009; Middleton et al., 2011; Jellinger and Attems, 2012) , and there is considerable overlap in the pathologies found in demented and non-demented patients (Fernando and Ince, 2004) . On the other hand, by age 80-85 years, many cognitively unimpaired subjects may have substantial cortical AD pathology (JL Price et al., 2009) , while others found significant positive correlation between the extent of dementia and senile plaque density (p=0.011), but not for the NFT density score (p=0.076) . Recent studies suggest that dementia in the oldest-old group (90+ years) is only modestly related to AD, while both cardiovascular and cerebrovascular pathology may cause cognitive impairment in most elders with low AD pathology scores (Jellinger, 2007b; Jellinger and Attems, 2010; Laukka et al., 2010) , and CVLs may contribute to the clinical expression of dementia (Strozyk et al., 2010) . However, several recent clinico-pathological studies clearly showed that Braak NFT staging remains a significant predictor of cognitive status even in oldest-old people (Dolan et al., 2010; Sinka et al., 2010) . There may be no evidence for a certain number of elderly subjects having dementia without an apparent causative morphologic background (Dolan et al., 2010; Jellinger and Attems, 2010) , although dementia lacking a known pathologic substrate is extremely rare .
In a retrospective clinicopathological study of 1100 demented seniors (66% females, MMSE <20; mean age at death 83.3±5.4 SD years, 90% over age 70 years) AD increased with highest incidence in the 8 th and 9 th decade, and slightly decreased after age 90, while the relative prevalence of both AD + minor cerebrovascular lesions and mixed dementia significantly increased with age (7.8 to 32.9% and 0 to 7.%, respectively, p<0.001). VaD showed a continuing age-related decrease from 15.6 to 9.4% (p<0.05), whereas AD + Lewy pathology remained fairly stable (10.3 and 11%) (Fig.  4) . In a prospective study of 180 demented patients (mean age 85±3.4 years), autopsy showed AD in 48%, AD with vascular pathology in 19%, VaD in 11%, DLB in 9%, and dementia of unknown etiology in 13% (Jellinger and Attems, 2010) , confirming the notion that a high percentage of demented persons aged 80+ do not met the pathological criteria of AD or were classified as "dementia of unknown etiology" (Crystal et al., 2000; Jellinger, 2001 ). Non-AD pathology significantly improved precise differentiation between oldest-old and younger age groups (Middleton et al., 2011) . 
Neuropathology findings in cognitively unimpaired aged subjects
It is increasingly recognized that the correlation between neuropathological lesions and cognitive impairment is modest and accounts for about a quarter of the variance in cognition of older adults. It has been hypothesized that the concept of resilient aging can be useful to understand mechanisms that underly healthy aging amidst disease-related pathology (Yankner et al., 2008) . Some individuals maintain normal cognitive function despite significant brain pathology, whereas others suffer varying degrees and neurological deterioration. Many aged people do not exhibit cognitive impairment and live "normal" lives despite displaying pathological changes that are characteristic of AD, PD, cerebrovascular disease or other disorders (Neuropathology-Group, 2001; O'Brien et al., 2009; Schneider et al., 2009; Bennett et al., 2012; Jellinger and Attems, 2012) .
Although the best morphological correlates of cognitive impairment/dementia are (1) the number of NFTs (Nelson et al., 2007; Duyckaerts et al., 2009; Serrano-Pozo et al., 2012) , and (2) loss of synapses (Scheff and Price, 1993; Scheff et al., 2006; Scheff et al., 2007) , between 8 and 45% of nondemented, often cognitively stable seniors were found to have AD-related pathologies (Morris et al., 1996; Davis et al., 1999; Green et al., 2000; Schmitt et al., 2000; Mitchell et al., 2002; Knopman et al., 2003a; Knopman et al., 2003b; O'Brien et al., 2009; JL Price et al., 2009; White, 2009; Serrano-Pozo et al., 2012) . Many of them showed only minimal to mild neuritic changes corresponding to Braak tau stages 0-IV (Braak and Braak, 1991) , while 31-88% showed NIA-RI criteria of no likelihood for AD criteria (Davis et al., 1999; Jentoft et al., 2011; Serrano-Pozo et al., 2012) . The frequency of intermediate likelihood of AD criteria ranged from 11.9 to 35.8% (Schmitt et al., 2000; Jentoft et al., 2011; Jellinger and Attems, 2012) , and only 1.5 to 3% were scored high likelihood of AD (Nelson et al., 2009; Jentoft et al., 2011) , while 18-25% met the CERAD criteria for AD (Davis et al., 1999; Schmitt et al., 2000; Knopman et al., 2003a; Knopman et al., 2003b) .
Review of the data from National Disease Coordinating Center (NDCC) database and the NUN study emphasized that there may be no documented examples of truly endstage neurofibrillary pathology with intact cognition . Although in the Adult Changes in Thought (ACT) and NUN studies, non-demented seniors with severe AD pathology (mean age 89 to 91 years) amounted to 8 and 12%, respectively, most of them showed neuritic Braak stage V and frontal NFT count was slightly lower than in a comparable dementia group . Review of the clinical data from these studies showed that most of the seniors classified as non-demented were indeed significantly memory-impaired (Barnes et al., 2006; Santacruz et al., 2011) . There is obviously no reported case of truly intact cognition despite severe AD-pathology, ie., widespread neocortical NFTs . A recent study of non-demented elderly demonstrated 62% with low and 28% with high NFT levels (Kramer et al., 2011) , whereas AD cases showed much higher cortical neuritic and striatal amyloid plaque scores . A 90+ study revealed significantly less severe Aβ, αSyn and TP'D-43 pathologies and hippocampal lesions in non-demented subjects, while Aβ distribution showed no esssential differences; non-demented individuals had limited hippocampal tau and neocortical Aβ pathology (Robinson et al., 2011) . On the other hand, NFTs in the occipital cortex of 24% of non-demented subjects aged 42-87 years were reported (Pikkarainen et al., 2009 ).
The presence of AD lesions in non-demented aged people may represent AD at a stage prior to clinical expression (presymptomatic, preclinical or unrecognized early stage (Morris et al., 1996; Troncoso et al., 1998; JL Price and Morris, 1999; Galvin et al., 2005; JL Price et al., 2009 ). This is supported by observations that the mechanisms responsible for these changes in non-demented elderly appear similar if not identical to those found in AD (Haroutunian et al., 1998; Troncoso et al., 1998) . The concept of "preclinical AD"pathology has been solidified by in vivo PET scanning, suggesting its high frequency in normal elderly similar to that seen in clinico-pathological cohorts (Mintun et al., 2006; Villemagne et al., 2008; Hampel et al., 2010; Johnson et al., 2012; Villain et al., 2012) . These data further suggest that preclinical stages are not static but progressive over time (Stomrud et al., 2010; Sojkova et al., 2011b; Beckett et al., 2012) .
Thus, mounting evidence from clinico-pathological studies support the view that AD is a continuous spectrum between between asymptomatic lesions in cognitively unimpaired elderly and dementia, with MCI as a transition between them . Although correlations between cognitive deficits and the severity and extension of plaques and tangles have been found (see , at least in those brains without other pathologies, the distinction between "physiological" (in non-demented subjects) and "pathological" aging (PA) may be difficult. Recent biochemical studies found excessive overlap with only subtle quantitative differences between amyloid levels, peptide profiles, solubility, and oligomeric assemblies in PA and AD brains , suggesting that PA represents an initial prodromal stage of AD. They further suggest that these individuals would develop clinical symptoms, if they live long enough, or have an inherent individual resistence to the toxic effect of Aβ (Moore et al., 2012) . A coding mutation (A6773T) in the APP gene that deduces the β-cleavage of APP may protect against AD and also against cognitive in the elderly without AD (Jonsson et al., 2012) .
A default hypothesis for AD is that it is part of a "normal aging process", such that plaques and tangles are secondary to aging or that the primary effect is on synapses and neurons independent of these morphological AD markers. AD is indeed a disease that accompanies human aging, but it is not an inevitable consequence of it (Swerdlow, 2007; Nelson et al., 2011) . However, the suggestion that plaques and NFTs, the morphologic markers of AD, may "cause" this disorder is oversimplified or even wrong, since accumulating evidence indicates that AD pathology represents effect rather than cause or at least a host response to injury, equaling adaptative or neuroprotective reaction (Castellani et al., 2008; Castellani et al., 2009a; Castellani et al., 2009b) . Larger brain and hippocampal values were associated with preserved cognitive function during life despite a high burden of AD pathology (Esiri and Chance, 2012; Negash et al., 2012; Arnold et al., 2013) , but the mechanisms that protect the elderly from AD are unknown (Erten-Lyons et al., 2009; Goh and Park, 2009 ) (see Jellinger and Attems, 2013) .
The AD resiliant group (pathological AD without cognitive impairment) showed preserved densities of synaptophysin-positive presynaptic terminals and dendritic spines compared with the AD-dementia group and increased densities of GFAP-positive astrocytes compared with the ADdementia group and normal controls (Arnold et al., 2013) . Hence, greater amounts of presynaptic proteins and distinct protein-protein interactions may be components of cognitive reserve reducing the risk of dementia with aging (Honer et al., 2012) . In conclusion, the aging process that results in loss of synapses and neurons may be far more detrimental for those with little cognitive/brain reserve as compared to those with a high one (Salthouse, 2009; Tucker and Stern, 2011) .
The importance of confounding pathologies
An important problem is the frequent presence of confounding processes in the aged brain that coexist with AD, as CVD, Lewy body pathology, argyrophilic grain disease, hippocampal sclerosis, and so forth, with about two-thirds of aged human brains containing non-AD-type neuropathology (Nagy et al., 1997a; White, 2009; Nelson et al., 2010a; Jellinger and Attems, 2012) , which, however, frequently have been missed clinically and could not be identified without neuropathological examination (Echavarri et al., 2012) . The high frequency of mixed pathologies in demented elderly was recently confirmed (Kovacs et al., 2008; . Since 50 to 85% of the brains of persons who die aged 80-90+ show appreciable CVLs (Petrovitch et al., 2005) , a specific problem is the impact of CVLs in relation to AD pathology (Chui et al., 2006; Giannakopoulos et al., 2007; Jellinger, 2007a, b; Schneider et al., 2007) . In several autopsy series of very old people, the frequency of AD ranged from 12 to 66%, that of VaD from 9 to 46.8%, that of DLB between 9 and 24%, and that of mixed pathologies between 2 and 86% (!), and was over 40% in a large autopsy series of patients over age 80 (Jellinger and Attems, 2010) .
The burden of vascular and AD type pathology are considered to be independent of each other, and are consistent with an additive or synergistic effect of both types of lesions on cognitive impairment (Schneider et al., 2004; Jellinger and Attems, 2006; Jellinger, 2007a, b; Duyckaerts et al., 2008; Launer et al., 2008; Strozyk et al., 2010) . The thresholds for vascular and degenerative lesions in distinguishing "pure" VaD or AD from mixed cases have been critically discussed (Zekry et al., 2003; Gold et al., 2007; Sinka et al., 2010) . AD pathology alone more frequently accounts for dementia than both microscopic and macroscopic infarcts (Troncoso et al., 2008) , and in advanced or fullblown stages of AD concomitant small vascular lesions do not significantly influence the overall state and progression of cognitive decline, the severity and extent of AD pathology overwhelming the effects of CVD (Lee et al., 2000; Bennett et al., 2005; Jellinger, 2007a Jellinger, , b, 2008a . In a recent autopsy study, global AD pathology significantly correlated to global cognition (p=0.008), whereas infarcts and Lewy bodies did not .
Many studies emphasize multiple confounding pathologies in non-demented elders, in particular CVLs, e.g. small or large cerebral infarctions, lacunes, and white matter lesions in up to almost 10% (Davis et al., 1999; Knopman et al., 2003b; Schneider et al., 2009; Jentoft et al., 2011) . Evaluation of 336 cognitively normal (CN) seniors from four studies revealed moderately to frequent neuritic plaque density in 47%, of these 6% also had Braak stages I to VI, medullary, nigral, and cortical Lewy bodies in 15,8 and 4%, respectively, cerebral microinfarcts in 33%, and high-level microinfarcts in 10%. The burden of brain lesions and comorbidities varied widely within each study but was similar across studies .
Among 418 non-demented partizipants of the Religious Order study (mean age 88.5±5.3 years), 35% showed macroscopic infarcts, 8% microinfarcts, 14.8% arteriosclerosis, 5.7% both, only 37.5% being free of CVLs (Buchman et al., 2011) . Up to 75% of CN seniors had various degrees of cerebral amyloid angiopathy (Jentoft et al., 2011) , argyrophilic grains in up to 23% (Jentoft et al., 2011) , Lewy pathologies in up to 18% (Schmitt et al., 2000; Knopman et al., 2003b; Schneider et al., 2009; White, 2009; Jellinger and Attems, 2012) , occasional hippocampal sclerosis (Schmitt et al., 2000; Jentoft et al., 2011) , and mixed pathologies in 7 to 15% (Schneider et al., 2009; White, 2009 ). Among 100 non-demented elderly ,mild, moderate and severe intracranial aterosclerosis was present in 31, 17 and 6%, respectively, lacunar state in basal ganglia and/or white matter in 73%, hippocampal sclerosis in 3%, Lewy bodies in 5%, tau pathology in brainstem in 60%, and mixed cerebral pathologies in 6%, whereas only 9% were free of CVLs . A recent British non-demented sample (n=53; mean age 81.5±7.4 years) showed maximum score neuritic plaques in 32-49%, NFTs in hippocampus and neocortex in 81 and 30.8%, respectively, white matter lesions in 55-83%, small vessel disease in 45%, infarcts in 13.7%, lacunes in 6%, and cerebral hemorrhages in 10% (Stephan et al., 2012) .
Nevertheless it should be borne in mind that all additional pathologies may interact, although their mutual impact often remains unclear. Therefore, the reliability and clinical relevance of the current diagnostic criteria need better qualification and validation. In addition, considerable phenotypical and morphological differences exist between genetic/familial and sporadic AD (Maarouf et al., 2008; Shepherd et al., 2009; Woodhouse et al., 2009; Martikainen et al., 2010) . A recent autopsy study investigating the association with upstream transcription factor 1 (USF1) genotype at a neuropathological level showed that USF1 carriers had lower NFT prevalence among 65+ year olds (Isotalo et al., 2012) . The synergistic interaction between Aβ, tau, and αSyn, accelerating neuropathology and cognitive decline, has been summarized recently (Jellinger, 2012a) .
Conclusions and future perspectives
There is increasing use of biochemical, genetic, and experimental approaches for refinement of diagnosis and analysis of the relevant contribution of different disease processes to neurodegeneration in AD and other dementias (see Marchesi, 2012) . Since the majority of degenerative dementing disorders are associated with intracellular and/or extracellular deposition of misfolded proteins, most of them can be classified and diagnosed by morphological, immunohistochemical and/or molecular (neurochemical) identification of these deposits representing characteristic markers or signposts of particular disorders. Algorithms for the molecular-pathological classification of sporadic (nongenetic/ nonhereditary) forms of neurodegenerative dementias have been proposed (Dickson, 2010; Jellinger, 2010b; . However, due to variable overlap, these changes may fail to distinguish between cognitively intact aged subjects from those with mild cognitive impairment (MCI) or preclinical or mild AD Markesbery, 2010; Scheff et al., 2011; Jicha et al., 2012; Mufson et al., 2012) . These latter groups show a wide variety in the intensity and pattern of AD-related lesions and other (vascular) pathologies (Schneider et al., 2009; Stephan et al., 2012) . Although they often differ from "normal" aging, only a small proportion of cognitively intact aged subjects are free of AD pathology, while up to 50% may show AD-related changes or even definite AD pathology (Arriagada et al., 1992; Davis et al., 1999; Knopman et al., 2003b; Bennett et al., 2006; JL Price et al., 2009) . Additional challenges arise from frequent coexistence with other pathologies that may have an additive or synergistic effect.
Neuropathology using immunohistochemistry, molecular biological and genetic methods can achieve a diagnosis or classification in up to 99%, using homogenous and harmonized definitions and standardized inter-laboratory methods, standards for the assessment of nervous system lesions, and considering exact clinical data. Interdisciplinary projects/initiatives for the standardized assessment of clinical, neuroimaging, biomarker, and neuropathological data are currently under way Frisoni, 2010; Jagust et al., 2010; Trojanowski et al., 2010; Weiner et al., 2010; Johnson et al., 2012; Toledo et al., 2012; Vanderstichele et al., 2012) . In the majority of cases except those with known genetic or metabolic backgrounds, however, pathological examination may not be able to clarify the causes or etiology of most dementing disorders (Jellinger, 2010a) , while some conservative authors emphasized that autopsy examination of well-studied cases of AD and other dementias still has a critical role to play (Esiri, 2010) . Therefore, based on current knowledge and future research, new and more exact criteria for the neuropathological diagnosis of neurodegenerative disorders are needed in order to find a way out of the current "chaos" regarding histological diagnosis of dementia and their clinical implications (Dubois et al., 2010; Jellinger, 2011) . Molecular genetics, biochemistry and animal models, at least in part reproducing the morphology of human AD and related disorders, have produced a large and convincing body of data on the pathogenesis and pathophysiology of these diseases, showing a complex cascade of events leading from preclinical to fully developed neurodegeneration (Gotz and Gotz, 2009; Leon et al., 2010; Balducci and Forloni, 2011; Petiet et al., 2011; de Calignon et al., 2012) . However, both their molecular backgrounds, basic etiologic factors, pathogenic interrelations of various concomitant pathologies and their impact on the manifestation of AD need further validation. Harmonized techniques are required to increase the accuracy and reproducibility of neuropathological diagnosis as a basis for further successful treatment and neuroprotection; an enormous challenge for modern neurosciences.
